Kubota Pharmaceutical Holdings Co., Ltd.
4596・Growth Market・Pharmaceuticals
Governance
Company with an Audit and Supervisory Committee. The Board of Directors consists of 4 members in total, 1 internal and 3 outside directors, resulting in an outside director ratio of 75%. The Audit and Supervisory Committee is composed of all 3 outside directors. There are no standing Nomination Committee or Compensation Committee established.
Risk Management
The Company does not maintain a standing risk management committee; the Board of Directors directly oversees the risk management process. The Audit and Supervisory Committee is responsible for monitoring and managing key financial risks, and receives risk reports from the CEO or management. Sustainability-related risks are managed in an integrated manner together with management risks.
Shareholder Returns
No dividends for both FY2025 (ending December 2025) and FY2026 (ending December 2026) (annual dividend of ¥0.00). Full-year earnings forecast has not been disclosed. No mention of share buybacks.
Dividend Policy
The annual dividend for FY2025 (ending December 2025) is ¥0.00 (no dividend). The forecast for FY2026 (ending December 2026) is also ¥0.00 (no dividend). The full-year earnings forecast is not disclosed as a reasonable estimate cannot be calculated at this time. No detailed dividend policy is stated.
ESG
While recognizing that the direct impact of climate change is limited, the company is promoting the digitalization and paperless operation of its business. It positions human capital as a key management resource, and is implementing initiatives such as a flextime system, stock options, on-the-job training (OJT), and the promotion of diversity. Quantitative ESG indicators and targets have not yet been established at this time.
Last updated: March 27, 2026